Critical Considerations of Residual CV Risk in Patients With T2D & ASCVD

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Critical Considerations of Residual CV Risk in Patients With T2D & ASCVD



ReachMD Healthcare Image

How can patients with T2D & ASCVD reduce their CV risk? Tune in to learn more.

  • Sponsored by

  • Overview

    Despite the decline of cardiovascular mortality in patients without type 2 diabetes (T2D), cardiovascular mortality remains a threat to those with both T2D and ASCVD even with A1c control.1 So joining Dr Jennifer Caudle to talk about some proactive measures these patients can take is Ms Melissa Magwire, Registered Nurse, Certified Diabetes Care Education Specialist, and the Program Director at the Cardiometabolic Center Alliance, Incorporated in Kansas City, Missouri.  


    1. Joseph JJ, Deedwania P, Acharya T, et al; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145(9):e722-e759. doi:10.1161/CIR.0000000000001040 

    Novo Nordisk is a registered trademark of Novo Nordisk A/S.
    © 2023 Novo Nordisk All rights reserved.
    US23DI00105 September 2023

Schedule18 Jul 2024